BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27353035)

  • 1. Myeloid neoplasms after chemotherapy and PRRT: myth and reality.
    Bodei L; Modlin IM; Luster M; Forrer F; Cremonesi M; Hicks RJ; Ezziddin S; Kidd M; Chiti A
    Endocr Relat Cancer; 2016 Aug; 23(8):C1-7. PubMed ID: 27353035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.
    Bodei L; Kidd M; Paganelli G; Grana CM; Drozdov I; Cremonesi M; Lepensky C; Kwekkeboom DJ; Baum RP; Krenning EP; Modlin IM
    Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):5-19. PubMed ID: 25273832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Decade of Experience.
    Kesavan M; Turner JH
    Cancer Biother Radiopharm; 2016 Aug; 31(6):189-98. PubMed ID: 27419665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yttrium-labelled peptides for therapy of NET.
    Bodei L; Cremonesi M; Grana CM; Chinol M; Baio SM; Severi S; Paganelli G
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S93-102. PubMed ID: 22388625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
    Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
    Kesavan M; Claringbold PG; Turner JH
    Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polish experience in Peptide receptor radionuclide therapy.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
    Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors.
    Bodei L; Kidd M; Prasad V; Modlin IM
    Front Horm Res; 2015; 44():198-215. PubMed ID: 26303714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review.
    Stolniceanu CR; Nistor I; Bilha SC; Constantin V; Simona V; Matovic M; Stefanescu C; Covic A
    Nucl Med Commun; 2020 Jul; 41(7):601-617. PubMed ID: 32404645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs.
    Bergsma H; van Vliet EI; Teunissen JJ; Kam BL; de Herder WW; Peeters RP; Krenning EP; Kwekkeboom DJ
    Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):867-81. PubMed ID: 23582925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
    J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm.
    Bober B; Saracyn M; Lubas A; Kolodziej M; Brodowska-Kania D; Kapusta W; Kaminski G
    Nucl Med Rev Cent East Eur; 2022; 25(1):54-61. PubMed ID: 35137938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide receptor radionuclide therapy of neuroendocrine tumours.
    Brabander T; Teunissen JJ; Van Eijck CH; Franssen GJ; Feelders RA; de Herder WW; Kwekkeboom DJ
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):103-14. PubMed ID: 26971847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.
    Hendifar AE; Delpassand ES; Kittleson MM; Tuli R
    Pancreas; 2018 Sep; 47(8):e55-e56. PubMed ID: 30113434
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
    Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of dose with toxicity and tumour response to
    Cremonesi M; Ferrari ME; Bodei L; Chiesa C; Sarnelli A; Garibaldi C; Pacilio M; Strigari L; Summers PE; Orecchia R; Grana CM; Botta F
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2426-2441. PubMed ID: 29785514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival and toxicity in patients with neuroendocrine tumors treated with
    Kennedy KR; Turner JH; MacDonald WBG; Claringbold PG; Boardman G; Ransom DT
    Cancer; 2022 Jun; 128(11):2182-2192. PubMed ID: 35363879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.